IL2 and myelodysplastic syndrome: Many other agents and drug combinations have been effective in immune-related therapy of MDS and include tissue necrosis factor-α (TNF-α) inhibitors and compounds that may bind with T-lymphocyte CD receptors and modify the expression of interleukin-2 and other cytokine production [34, 60].